Fingolimod

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Fingolimod or Gilenya (brand name) is a drug licensed for use in adults and children aged over 20 with relapsing-remitting multiple sclerosis.[1] Fingolimod may module TRPM7.

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

No clinician trials have been conducted for ME/CFS patients using fingolimod.

Costs and availability[edit | edit source]

Perscription only drug.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]